Active Ingredient: Bromazepam
Bromazepam is indicated for anxiety. Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Regimen A
Oral, between 1.5 milligrams bromazepam and 3 milligrams bromazepam, 1 to 3 times daily, over the duration of 8 to 12 weeks.
Regimen B
Oral, between 6 milligrams bromazepam and 12 milligrams bromazepam, 2 to 3 times daily, over the duration of 8 to 12 weeks.
Treatment should be as short as possible. The overall duration of treatment generally should not be more than 8–12 weeks, including a tapering off process.
These amounts are general recommendations, and dosage should be individually determined. Treatment of outpatients should begin with low doses, gradually increasing to the optimum level. The patient should be reassessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free.
In certain cases, extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient's status with special expertise.
The lowest dose which can control symptoms should be used.
The optimum dosage and frequency of administration of bromazepam should be based on the individual patient, the severity of symptoms and previous psychotropic drug history.
The usual dosage in general practice is from 3 mg to 18 mg daily in divided doses.
In exceptional circumstances, in hospitalised patients, up to the maximum daily dosage of 60 mg in divided doses, may be given.
A reduction in dose for elderly patients is recommended. Treatment should always be tapered off gradually. Patients who have taken benzodiazepines for a prolonged time may require a longer period during which doses are reduced. Specialist help may be appropriate.
Elderly patients require lower doses because of individual variations in sensitivity and pharmacokinetics; doses should not exceed half those normally recommended.
Bromazepam should not be used in children less than 12 years of age. The safety and efficacy of bromazepam in children less than 12 years has not been established.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.